ALBO News and Press, Albireo Pharma Inc. From 11/03/21

ABC, ABUS, ACIW, ADAP, AES, AHCO, AKBA, ALBO, ALE, APD, APTV, ARW, ASPS, ATNX, ATRA, ATRS, BCE, BDX, BLDR, BLI, BLL, BRG, BXRX, CARS, CCOI, CFX, CHH, CI, CLDT, CMRX, CNHI, CNP, CNQ, COMM, CPE, CS, CTXS, CWEN, CYBR, DBRG, DEN, DIN, DISH, DLX, DNB, DOCN, DUK, EPAM, ERJ, ESTE, EURN, EVA, FIS, FW...

Albireo Pharma (NASDAQ:ALBO) is scheduled to announce Q3 earnings results on Thursday, November 4th, before market open. The consensus EPS Estimate is $0.49 and the consensus Revenue Estimate is $17.05M (+700.5% Y/Y). Over the last 3 months, EPS estimates have seen 4 upward revisions and 3 do...

BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on November 4, 2021, to provide a ...

– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases – – Phase 3 Bylvay™ (odevixibat) data presentations on long-term treatment benefits show evidence of improved liver health and function across PFIC type...

– Agreement to accelerate commercialization of Bylvay ™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia – – Albireo to receive upfront payment of $15M and up to $120M in milestones and doub...

BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support pati...

– Listed on the German national price list and all pharmacy software programs – – Bylvay is approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug indicated to treat all forms of ...

– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug indicated to treat all forms of PFIC – – MHRA decision based on data from the largest Phase 3 PFIC trial to dat...

– PRV was granted to Albireo with the FDA approval of Bylvay TM (odevixibat) in July – – Non-dilutive capital further strengthens the Company’s financial position – BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc....

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, Simon Harford, Chief Financial Officer and other members of t...